Latest News

AstraZeneca may be subject to further import tax penalties from China

AstraZeneca may be subject to further import tax penalties from China

AstraZeneca said on Tuesday that it could face a fine up to $8,000,000 for suspected unpaid import tax in China. The drugmaker is working to boost its business in China, its second largest market, after scandals such as the arrest of the company's China president last summer.

AstraZeneca, despite having a robust pipeline, is facing headwinds from its two largest markets: the United States and China. These include scandals in China and possible U.S. Tariffs on pharmaceuticals, as well as a trade conflict between Beijing and Washington.

AstraZeneca reported that authorities in Shenzen had informed it that the unpaid amount suspected was $1.6 million. A fine between one and five times this amount could be imposed if found guilty.

The company stated that "to the best AstraZeneca knows" the importation tax referred to in the opinion related to Enhertu, its breast cancer drug.

AstraZeneca's core profit for the quarter ended March 31 was $2.49, beating analyst expectations. However, total revenue of $13.59bn missed analysts' estimates.

In February, the company said that it could be fined up to $4.5million in China for suspected unpaid import duties, relating to cancer drugs Imfinzi, and Imjudo. It added that this probe could extend to Enhertu.

AstraZeneca said on Tuesday that authorities had informed it that there was no "illegal profit" for AstraZeneca based on a separate allegation of personal information breach.

(source: Reuters)